Equillium, Inc. announced on August 4, 2025, a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. The company stated this move is for diversification, liquidity, and long-term capital appreciation potential.
As of June 30, 2025, Equillium reported approximately $11.5 million in cash and cash equivalents. The company expects its existing cash to fund operations only into the fourth quarter of 2025, based on implemented operating changes to decrease expenditures and conserve cash.
Despite this new financial strategy, Equillium stated it would continue its biotech mission to advance life-changing therapeutics, specifically preparing EQ504 for clinical development. The company plans to provide additional updates on this strategy during the third quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.